BLFS
BioLife Solutions, Inc.
NASDAQ · Healthcare · Medical - Instruments & Supplies · US
$35.25
−0.79%Year over year
Reported trailing growth
- Revenue
- +34.4%
- EBITDA
- +249.0%
- EBIT
- +141.3%
- EPS
- +1071.8%
- Free cash flow
- —
- Operating cash flow
- +8.6%
Forward estimates
Based on analyst estimates
- Revenue
- +20.3%
- EBITDA
- +65.7%
- EPS
- -76.5%
Three-year CAGR
- Revenue
- +8.1%
- EBITDA
- +135.4%
- EBIT
- +84.8%
- Net income
- +39.9%
- EPS
- +43.2%
- Free cash flow
- -92.0%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026